Why Progestogen Must Be Added to Estrogen in Postmenopausal Women with an Intact Uterus
Progestogen is added to estrogen therapy in postmenopausal women with an intact uterus to prevent endometrial cancer—unopposed estrogen increases endometrial cancer risk 10- to 30-fold after 5 years, while adding progestogen reduces this risk by approximately 90%. 1, 2
The Fundamental Problem: Unopposed Estrogen and Endometrial Cancer
Estrogen stimulates endometrial proliferation. When given alone to women with a uterus, this creates a dangerous situation:
- Unopposed estrogen raises endometrial cancer risk with a relative risk of 2.3 (95% CI 2.1-2.5) after just one year 1
- After 10 years of unopposed estrogen use, the risk escalates to approximately 9.5-fold 1
- This elevated risk persists for 5 or more years even after stopping unopposed estrogen 1
- In clinical trials, 64% of women receiving estrogen alone developed endometrial hyperplasia within 36 months, compared to only 6% when progestogen was added 2
How Progestogen Provides Protection
Progestogen opposes estrogen's proliferative effects on the endometrium by inducing secretory transformation and preventing hyperplasia:
- Adding progestogen reduces endometrial cancer risk by approximately 90% compared to unopposed estrogen 1, 3
- The protective effect requires adequate dose AND duration—progestogen must be given for at least 12 days per cycle in sequential regimens 4, 1
- Regimens providing fewer than 12 days of progestogen per cycle increase endometrial cancer risk by approximately 1.8-fold 1
Evidence-Based Progestogen Regimens
First-Line Recommendation
Micronized progesterone 200 mg orally at bedtime is the preferred progestogen because it provides adequate endometrial protection while offering superior breast safety compared to synthetic progestins 1, 2
This can be given as:
- Sequential: 200 mg for 12-14 days each 28-day cycle 1
- Continuous: 100-200 mg daily without interruption 1
Alternative Options
- Medroxyprogesterone acetate 10 mg daily for 12-14 days per month (sequential) 1, 5
- Medroxyprogesterone acetate 2.5 mg daily (continuous combined) 1, 5, 2
- Transdermal levonorgestrel 10 μg daily (combined patches) 1
Why Women Without a Uterus Don't Need Progestogen
Estrogen-alone therapy is appropriate for women who have had a hysterectomy because there is no endometrium to protect 1, 6
In fact, adding progestogen in this situation creates unnecessary risks:
- Estrogen-alone therapy in women without a uterus shows NO increased breast cancer risk and may even be protective (RR 0.80) 4, 1, 6
- Combined estrogen-progestogen therapy adds 8 additional invasive breast cancers per 10,000 women-years 1
- Progestogens may diminish some beneficial cardiovascular effects of estrogen 7, 8
Critical Clinical Pitfalls to Avoid
Never prescribe estrogen-alone therapy to women with an intact uterus—this dramatically increases endometrial cancer risk and is considered medical malpractice 1
Do not use progestogen regimens shorter than 12 days per cycle in sequential therapy—this provides inadequate endometrial protection 4, 1
Avoid compounded bioidentical hormones, as their safety and effectiveness for endometrial protection have not been established through proper drug approval processes 5
The Bottom Line
The addition of progestogen to estrogen therapy in women with a uterus is not optional—it is mandatory to prevent a well-documented, substantial increase in endometrial cancer risk. The choice of which progestogen, dose, and regimen can be individualized based on tolerability and other risk factors, but the principle of endometrial protection is absolute. 1, 2, 3, 8